Short answer
Bioventus Inc. (BVS) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Bioventus financial results for the three and nine months ended September 26, 2026.
Bioventus Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Bioventus financial results for the three and nine months ended September 26, 2026
- Exhibit 99.1 contains the detailed quarterly and year-to-date results for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $142.4M, up 3%; Pain Treatments led growth at 6.2%, while Restorative Therapies declined 3.4%
- GAAP EPS $0.08 versus $0.05, with net income attributable to Bioventus rising to $6.0M from $3.2M
- Adjusted EBITDA $28.4M, up 7%; operating cash flow $20.7M supported debt reduction
- $15.0M discretionary term-loan prepayment lowers future interest costs and improves credit metrics
- Strategic-alternatives review continues, creating potential shareholder value but adding transaction uncertainty and $0.4M of cash costs in Q3
- 2026 net-sales guidance reduced to $590M-$595M, while adjusted EPS guidance remains $0.75-$0.79 per diluted share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bioventus Inc. 8-K filings
Get the next BVS 8-K as it lands
Follow BVS for push alerts, or ask the research agent what this filing means.